Business · 28/04/2004Updated: 10/17/2026 · 1 min read

FDA Releases Draft Guidance for Exocrine Pancreatic Insufficiency Drug Products

The Food and Drug Administration (FDA) has made available a draft guidance document to help pharmaceutical companies submit new drug applications for exocrine pancreatic insufficiency drug products, which are now classified as new drugs requiring approved NDAs for marketing.